Pfizer Inc. and India's Ranbaxy Laboratories Ltd. said Wednesday they have settled their patent dispute over the blockbuster cholesterol drug Lipitor, delaying the release of generic versions in the United States until Nov. 30, 2011. Pfizer's Lipitor is the world's best-selling drug, generating nearly $13 billion in 2007 sales. The settlement enables Ranbaxy to make and launch a generic before Lipitor's crystalline and amorphous patents expire in 2016 and 2017.
June 18, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Pfizer Inc. and India’s Ranbaxy Laboratories Ltd. said Wednesday they have settled their patent dispute over the blockbuster cholesterol drug Lipitor, delaying the release of generic versions in the United States until Nov. 30, 2011.
Pfizer’s Lipitor is the world’s best-selling drug, generating nearly $13 billion in 2007 sales.
Presented by BigVoodoo
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
